Genfit Adr (GNFT)

Sep 29, 2025

European ADRs Start The Week With Small Gains Stateside - Finimize

Sep 29, 2025

Sep 27, 2025

FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright - Defense World

Sep 27, 2025

Sep 26, 2025

FY2025 EPS Estimates for GENFIT Lifted by Leerink Partnrs - Defense World

Sep 26, 2025

Sep 26, 2025

HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings - MarketBeat

Sep 26, 2025

Sep 25, 2025

GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World

Sep 25, 2025

Sep 24, 2025

HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat

Sep 24, 2025

Sep 11, 2025

European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize

Sep 11, 2025

Aug 20, 2025

GENFIT (NASDAQ:GNFT) Coverage Initiated by Analysts at HC Wainwright - Defense World

Aug 20, 2025

Aug 15, 2025

European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest

Aug 15, 2025

Jul 10, 2025

GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World

Jul 10, 2025

Jun 30, 2025

European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest

Jun 30, 2025

Jun 27, 2025

European Biopharma Leads Gains In ADR Market Surge - Finimize

Jun 27, 2025

Jun 27, 2025

European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest

Jun 27, 2025

May 31, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

May 31, 2025

May 22, 2025

European ADRs Show Optimism As Genfit Leads Gains - Finimize

May 22, 2025

May 07, 2025

European ADRs See Mixed Results With Modest Gains - Finimize

May 07, 2025

Apr 11, 2025

European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView

Apr 11, 2025

Apr 09, 2025

European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize

Apr 09, 2025

Apr 08, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView

Apr 08, 2025

Apr 03, 2025

European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView

Apr 03, 2025

Apr 01, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView

Apr 01, 2025

Mar 27, 2025

European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView

Mar 27, 2025

Mar 26, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView

Mar 26, 2025

Mar 24, 2025

European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView

Mar 24, 2025

Mar 14, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView

Mar 14, 2025

Mar 03, 2025

European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView

Mar 03, 2025

Feb 28, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView

Feb 28, 2025

Jun 10, 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - GlobeNewswire

Jun 10, 2024

Dec 07, 2023

Ipsen confirms U.S. FDA grants priority review for New Drug - GlobeNewswire

Dec 07, 2023

Nov 13, 2023

Results from Ipsen’s ELATIVE® pivotal Phase III trial of - GlobeNewswire

Nov 13, 2023

Jun 30, 2023

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen

Jun 30, 2023

Dec 17, 2021

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire

Dec 17, 2021